RESUMEN
BACKGROUND: Matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) are two proteins involved in angiogenesis. In the present study we investigated the association of pretreatment MMP-9 and VEGF serum levels with clinicopathological parameters and outcome in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: From February 1998 to October 1999, pretreatment serum levels of MMP-9 and VEGF were analysed in 118 patients with enzyme-linked immunoassays. At diagnosis 50 patients (42%) were staged as early disease (I/II), 27 patients (23%) as locally advanced (IIIA/IIIB), and 41 patients (35%) had metastatic disease (IV). In 72 of the 118 patients tumours were resected and 46 patients received combination chemotherapy with gemcitabine and vinorelbine. RESULTS: The median survival of all 118 patients was 602 days. The 72 patients who had undergone surgery had a median survival of 972 days and the 46 patients who were treated with chemotherapy had a median survival of 298 days (P <0.001). Resected patients with stage I/II disease and an MMP-9 serum level Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico
, Biomarcadores de Tumor/análisis
, Carcinoma de Pulmón de Células no Pequeñas/patología
, Desoxicitidina/análogos & derivados
, Factores de Crecimiento Endotelial/sangre
, Péptidos y Proteínas de Señalización Intercelular/sangre
, Neoplasias Pulmonares/patología
, Linfocinas/sangre
, Metaloproteinasa 9 de la Matriz/sangre
, Vinblastina/análogos & derivados
, Adulto
, Anciano
, Anciano de 80 o más Años
, Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico
, Desoxicitidina/administración & dosificación
, Ensayo de Inmunoadsorción Enzimática
, Femenino
, Estado de Salud
, Humanos
, Neoplasias Pulmonares/tratamiento farmacológico
, Masculino
, Persona de Mediana Edad
, Estadificación de Neoplasias
, Pronóstico
, Sobrevida
, Resultado del Tratamiento
, Factor A de Crecimiento Endotelial Vascular
, Factores de Crecimiento Endotelial Vascular
, Vinblastina/administración & dosificación
, Vinorelbina
, Gemcitabina
RESUMEN
The hand-foot syndrome (palmar-plantar erythrodysesthesia) is a side-effect which is associated with several cytotoxic agents (e.g. 5-fluorouracil, UFT, capecitabine, cytarabine, doxorubicin, liposomal-encapsulated doxorubicin). An association with a prolonged infusion of high doses of vinorelbine has also been described. To date a hand-foot syndrome after gemcitabine or short infusions of vinorelbine has not been reported before. The patient described here had a non-small-cell lung cancer stage IIIB disease and developed a hand-foot syndrome after short infusions of standard-dose chemotherapy of a combination with gemcitabine and vinorelbine.